Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Enlivex Therapeutics Ltd (ENLV)
NASDAQ:ENLV
Enlivex (ENLV) Stock Price & Analysis
335 Followers
ENLV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.51 - $6.15
Previous Close$2.65
Volume19.23K
Average Volume (3M)33.77K
Market Cap
$48.73M
Enterprise Value$2.68M
Total Cash (Recent Filing)$50.24M
Total Debt (Recent Filing)$4.19M
Price to Earnings (P/E)-1.6
Beta1.15
Next Earnings
Aug 07, 2023EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding13,463,771
10 Day Avg. Volume21,120
30 Day Avg. Volume33,771
Standard Deviation0.28
R-Squared0.03
Alpha-0.00033
Financial Highlights & Ratios
Price to Book (P/B)0.85
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.15
Forecast
1Y Price Target
$15.00Price Target Upside467.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Enlivex News
Press ReleasesEnlivex Appoints Andrew Singer to its Board of Directors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ENLV FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was $2.51 and its highest was $6.15 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Currently, no data Available
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is Aug 07, 2023 which is in 65 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on May 26, 2023. The company reported -$0.4 earnings per share for the quarter, the consensus estimate of -$0.4 by $0.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 18,421,852 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -$0.4 in its last earnings report, expectations of -$0.4. Following the earnings report the stock price went down -3.008%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Among the largest hedge funds holding Enlivex Therapeutics Ltd’s share is ARK Investment Management LLC. It holds Enlivex Therapeutics Ltd’s shares valued at N/A.
---
Enlivex Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (467.11% Upside)
$15.00 (467.11% Upside)
Blogger Sentiment
Bullish
ENLV Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 331.0K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.44%
12-Months-Change
Fundamentals
Return on Equity
-43.78%
Trailing 12-Months
Asset Growth
-28.91%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.
---
---